 |
|
|
| |
PREDICTORS OF SUSTAINED VIRAL RESPONSE TO 4-6 WEEK DURATION THERAPY WITH LEDIPASVIR + SOFOSBUVIR + GS-9451 +/- GS-9669 IN EARLY AND ADVANCED FIBROSIS (NIH/UMD SYNERGY TRIAL)
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Sarah Kattakuzhy* 1, Sreetha Sidharthan1, Eleanor Wilson2, Angie Price1, Rachel Silk1, Chloe Gross1, Elizabeth Akoth1, Eric Meissner3, Gebremariam Teferi4, Veronica Jenkins5, Phil Pang6, Hongmei Mo6, Anu Osinusi6, Henry Masur7, Shyamasundaran Kottilil1, Anita Kohli2
1Department of Infectious Diseases, University of Maryland/Institute of Human Virology, Baltimore, 2Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, 3Division of Infectious Diseases, Medical University of South Carolina, Charleston, 4Infectious Disease, Unity Healthcare, Inc., 5Department of Medicine, Family Medical Counseling Services, Inc., Washington, DC, 6Gilead Sciences, Foster City, CA, 7Critical Care Department, National Institutes of Health, Bethesda, United States
|
| |
|
|
|
|
|
